DelveInsight’s “Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Bipolar Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bipolar Depression Market Forecast
Some of the key facts of the Bipolar Depression Market Report:
- The Bipolar Depression market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the National Institute of Mental Health (NIMH), a division of the National Institutes of Health (NIH), the 12-month prevalence of bipolar disorder among US individuals 18 and older was estimated to be 2.8% based on diagnostic interview data from the National Comorbidity Survey Replication (NCS-R). Additionally, it mentioned that 4.4% of US adults are thought to have bipolar disorder at some point in their lives
- The incidence of bipolar disorders across the globe is 2.4%, according to the French organization HAS, with equal prevalence in the United States, Europe, and Asia. According to estimates, bipolar disorder affects between 1% and 2.5% of people in France
- In the year 2021, there were 2,380.8 Thousand (K) diagnosed and treated cases of bipolar depression in the United States. It is predicted that this number would rise in the years to come.
- Key Bipolar Depression Companies: AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
- Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
- The number of cases of each type of bipolar depression in the US in 2021 was 934.9K for bipolar depression I and 1445.9K for bipolar depression II, respectively
- The Bipolar Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bipolar Depression pipeline products will significantly revolutionize the Bipolar Depression market dynamics.
Bipolar Depression Overview
A mental illness known as bipolar disorder (BD) is characterised by mood swings between mania and depression. Bipolar disorder (BD) is primarily divided into BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS) based on the characteristics of the episodes.
Get a Free sample for the Bipolar Depression Market Report:
https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
Bipolar Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bipolar Depression Epidemiology Segmentation:
The Bipolar Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Bipolar Depression
- Prevalent Cases of Bipolar Depression by severity
- Gender-specific Prevalence of Bipolar Depression
- Diagnosed Cases of Episodic and Chronic Bipolar Depression
Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Epidemiology Forecast
Bipolar Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched during the study period. The analysis covers Bipolar Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market :
The report also covers the Bipolar Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bipolar Depression Therapies and Key Companies
- NRX-100/ NRX-101: NeuroRx
- SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
- COMP 360 (Psilocybin Therapy): COMPASS Pathways
- Sage-217: SAGE Therapeutics
- cariprazine: Forest Laboratories
- Ketamine Hydrochloride: Target Health Inc.
- Lurasidone HCl: Vanguard, Inc.
- Quetiapine Fumarate (SEROQUEL): AstraZeneca
- Esketamine: Celon Pharma SA
- Lumateperone: Intra-Cellular Therapies, Inc.
- Brexpiprazole: Otsuka America Pharmaceutical
- OSU6162: Arvid Carlsson Research AB
- Bifeprunox: Solvay Pharmaceuticals
- carbamazepine ER: Shire
- ITI-007 (Lumateperone): Intra-Cellular Therapies, Inc.
- Olanzapine Fluoxetine Combination (OFC): Eli Lilly and Company
- lamotrigine: GlaxoSmithKline
- FK949E: Astellas Pharma Inc
- SM-13496: Sumitomo Pharma Co., Ltd.
Discover more about therapies set to grab major Bipolar Depression market share @ Bipolar Depression Treatment Market
Bipolar Depression Market Drivers
- Future Directions in Blood Biomarkers
- Increase in Awareness and Technology
- Advances Toward Precision Medicine for Bipolar Depression
Bipolar Depression Market Barriers
- Misdiagnosis of Bipolar Depression
- Unsatisfactory Design of RCTs
- Limited Understanding of the Disease Mechanism
Scope of the Bipolar Depression Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Bipolar Depression Companies: AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
- Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
- Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
- Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Bipolar Depression Unmet Needs, KOL’s views, Analyst’s views, Bipolar Depression Market Access and Reimbursement
To know more about Bipolar Depression companies working in the treatment market, visit @ Bipolar Depression Clinical Trials and Therapeutic Assessment
Table of Contents
1. Bipolar Depression Market Report Introduction
2. Executive Summary for Bipolar Depression
3. SWOT analysis of Bipolar Depression
4. Bipolar Depression Patient Share (%) Overview at a Glance
5. Bipolar Depression Market Overview at a Glance
6. Bipolar Depression Disease Background and Overview
7. Bipolar Depression Epidemiology and Patient Population
8. Country-Specific Patient Population of Bipolar Depression
9. Bipolar Depression Current Treatment and Medical Practices
10. Bipolar Depression Unmet Needs
11. Bipolar Depression Emerging Therapies
12. Bipolar Depression Market Outlook
13. Country-Wise Bipolar Depression Market Analysis (2019–2032)
14. Bipolar Depression Market Access and Reimbursement of Therapies
15. Bipolar Depression Market Drivers
16. Bipolar Depression Market Barriers
17. Bipolar Depression Appendix
18. Bipolar Depression Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/